To the Editor JAMA Cardiology recently initiated an ongoing discussion regarding the prevalence and significance of postvaccination myocarditis (PVM) in adolescents and the role that physicians and policy makers should play in communicating the risks of vaccination or nonvaccination to patients. We strongly agree with the position put forth by Navar et al1 that (1) the societal benefit of mass vaccination is overwhelming and (2) increased PVM reporting should be viewed as a reflection of increased surveillance and a working Vaccine Adverse Event Reporting System.